<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934739</url>
  </required_header>
  <id_info>
    <org_study_id>T1306</org_study_id>
    <nct_id>NCT00934739</nct_id>
  </id_info>
  <brief_title>A Study of High-Risk Oral Cavity Cancer</brief_title>
  <official_title>Multicentre，A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        1. To study the effect of anti-angiogenesis therapy on reducing the recurrence of high-risk
           oral cavity cancer patients after curative local treatment.

        2. To study the toxicity and compliance of post-operative anti-angiogenesis therapy

      Study design:

      This is a multi-center randomized controlled phase II/III two-stage study.

      Study endpoints:

      The primary endpoint is the tumor-free survival (primary and second primary malignancies) and
      the primary analysis is to compare the tumor-free survival between groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type and number of patients:

      Patients with resectable oral cancer of clinical stage N2, 3 or skin-involved T4 will be
      enrolled.

      Sample size at the first stage is 64 patients per group and the total sample size at the end
      of the second stage is 192 patients per group, assuming that the accrual rate/hazard rate =
      1.33, an α=0.05 and power of 0.8 (Hypotheses: H0:θ ≦ 1.0 and Ha: θ ≧ 1.33)

      Treatment schedule:

      Group A：standard postoperative concurrent chemoradiotherapy.

      Group B：Immediately after operation starts thalidomide (50) 4# per day and celecoxib (200) 2#
      bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy.

      Group C：Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone
      (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent
      chemoradiotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the tumor-free survival that is defined as the duration between the dates of operation and the date of disease recurrence.</measure>
    <time_frame>7 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical examinations, lab abnormality and other toxicities graded by the NCI Common Toxicity Criteria will be examined to evaluate safety profiles of the study treatments.</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Oral Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard postoperative concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thalidomide, Celebrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant anti-angiogenesis therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide, Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant anti-angiogenesis therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide, Celebrex</intervention_name>
    <description>Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy</description>
    <arm_group_label>Thalidomide, Celebrex</arm_group_label>
    <other_name>Adjuvant Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Dexamethasone</intervention_name>
    <description>Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy</description>
    <arm_group_label>Cyclophosphamide, Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proved oral cavity squamous cell carcinoma (buccal and mobile tongue).

          2. Clinical stage T4a with skin involvement or resectable N2-3 by UICC/AJCC 1997 staging
             system.(24)

          3. Curative-intent operation feasible and arranged.

          4. Eastern Cooperative Oncology Group performance status ≦ 1.

          5. A leukocyte count ≧3750/μL, Hb ≧10 g/dL, and a platelet count ≧100,000/μL.

          6. A serum bilirubin level &lt; 1.5 UNL (upper normal limit), serum creatinine level &lt; 1.5
             UNL or creatinine clearance &gt; 60 mL/min.

          7. Age less than 70 years old

          8. Informed consent signed.

        Exclusion Criteria:

          1. Evidence of distant metastatic.

          2. Presence of another malignancy other than treated squamous/basal cell carcinoma of the
             skin.

          3. Presence of uncontrolled hypertension, poorly controlled heart failure.

          4. Presence of active infection.

          5. Patients who have been or are being treated with chemotherapy, radiotherapy,
             immunotherapy, or other experimental therapies.

          6. Women who test positive for pregnancy. Note: Patients received neck lymph node biopsy
             will be eligible and the stage will be given according to the preoperative status.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruey-Long Hong, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-Risk Oral Cavity Cancer,</keyword>
  <keyword>Anti-Angiogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

